Intelligent Bio Solutions reports preliminary Q2 revenue $610,000

Expects Q2 Gross profit to increase 32.6% from $0.43 million to $0.57 million for the six months ended December 31, 2024. “Our strong financial performance underscores the momentum we are building. Despite quarterly fluctuations, our total calendar year revenue grew 23% year-on-year, reflecting our sustained upward trajectory. More importantly, our strategic focus on higher-margin cartridge sales is driving a significant 11-point expansion in gross profit margin, reinforcing the strength of our business model,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions (INBS). “As we continue scaling, our growing base of 400+ accounts and international expansion efforts position us for sustained profitability and long-term success.”